- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07941349
Comparison of Continuous Cardiac Rhythm Monitoring and Standard Care in Post-MI Patients With Significant Scar and Reduced LVEF (PRAETORIAN-LUX)
Prospective Randomized Comparison of Standard Care Versus Continuous Cardiac Rhythm Monitoring of Patients With Significant Myocardial Scar and Moderately Reduced Ejection Fraction After Myocardial Infarction
After myocardial infarction (MI), reduced LVEF (≤35%) is a known risk marker for sudden cardiac death (SCD), yet many SCD cases occur with LVEF >35% as myocardial scarring remains a strong arrhythmogenic substrate regardless of preserved function. Non-sustained ventricular tachycardias ((NS)VTs) predict malignant arrhythmias and highlight the importance of early detection.
The primary objective is to determine whether continuous cardiac rhythm monitoring after myocardial infarction improves the detection of cardiac arrhythmias that require medical intervention by conducting a prospective, multi-center, international, randomized trial.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
After myocardial infarction (MI), reduced left ventricular ejection fraction (LVEF ≤35%) is a well-known risk factor for sudden cardiac death (SCD), but many SCD cases occur in patients with preserved or mildly reduced LVEF (>35%) due to the arrhythmogenic potential of myocardial scar tissue. Non-sustained ventricular tachycardia (NSVT) is an early marker of malignant arrhythmias, underscoring the value of continuous rhythm monitoring. This prospective, multicentre, randomized trial investigates whether continuous cardiac rhythm monitoring using an implantable loop recorder in post-MI patients with LVEF >35 ≤50% and proven myocardial scar improves detection of clinically relevant arrhythmias compared with standard care. Secondary aims include evaluating the incidence of NSVT/VT/VF, premature ventricular contraction (PVC) burden, and the prognostic value of biomarkers such as NT-proBNP, Lp(a), IL-6, and CRP, as well as assessing patient safety perception and the potential health benefits of early intervention.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Reinoud E Knops, Professor, MD, PhD
- Telefonnummer: +31205666555
- E-post: r.e.knops@amc.nl
Studer Kontakt Backup
- Navn: Mashhour Hosny, MD, MSc
- Telefonnummer: +31205665424
- E-post: m.hosny@amsterdamumc.nl
Studiesteder
-
-
North Holland
-
Amsterdam, North Holland, Nederland, 1105
- Rekruttering
- Amsterdam Medical Center Amsterdam
-
Ta kontakt med:
- Mashhour Hosny, MD, MSc
- Telefonnummer: 31(0)205665550
- E-post: m.hosny@amsterdamumc.nl
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Patients ≥ 18 years of age with a recent (≤ 12 months) STEMI or NSTEMI according to the definition by current ESC/AHA guidelines
-
LVEF >35-≤50% measured > 48 hours after index STEMI or NSTEMI
o In case a candidate has an LVEF <35% after a recent MI, the responsible physician can decide to treat the patient with GDMT first and reassess the LVEF after 3 months post-MI
-
Clinically relevant myocardial scar, identified by one of the following criteria:
- Post-MI TTE: Akinetic or dyskinetic myocardial segments seen on two anatomically adjacent echocardiographic segments suggestive for ischemic scar
- Post-MI ECG: Pathologic Q-waves of ≥0.04 seconds in duration and ≥25% of the R wave amplitude in at least two contiguous leads
- Post-MI MRI: Late gadolinium enhancement (LGE) in a typical ischemic distribution pattern, characterized by subendocardial or transmural involvement in at least one myocardial segment corresponding to a coronary artery territory, and confirmed on two orthogonal imaging planes
- Post-MI nuclear imaging: Severely reduced perfusion and absent of metabolic activity in two or more contiguous segments, with tracer uptake less than 50%
Exclusion Criteria:
- Patients implanted with any CIED or with a guideline indication for a CIED
- Indication for chronic renal dialysis
- Patients with life expectancy shorter than 12 months due to any medical condition
- NYHA Class IV
- Participation in another trial that may interfere
- Woman who are pregnant or breast feeding
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Screening
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Implantable Cardiac Monitor arm
Patients undergoing an ICM implant for continuous cardiac monitoring |
Implantable cardiac monitor implantation for continuous monitoring |
|
Ingen inngripen: Control group
Control group with standard of care without ICM implant |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Time to first documented cardiac arrhythmia prompting medical intervention
Tidsramme: Throughout the planned 36-month participant follow-up period.
|
Composite endpoint defined as the first documented cardiac arrhythmia that prompts a clinical action, including a change in medication, a diagnostic or interventional procedure, or hospitalization. Each participant contributes only their first qualifying event, regardless of arrhythmia type or clinical action. The outcome will be reported as the cumulative incidence of this composite event, expressed as a percentage, and compared between the insertable cardiac monitor (ICM) and standard-care groups using time-to-event analysis. |
Throughout the planned 36-month participant follow-up period.
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of participants with non-sustained ventricular tachycardia, ventricular tachycardia, or ventricular fibrillation
Tidsramme: Throughout the planned 36-month participant follow-up period.
|
Composite endpoint comprising documented non-sustained ventricular tachycardia (NSVT), ventricular tachycardia (VT), or ventricular fibrillation (VF). A participant meets the endpoint upon documentation of any component and is counted once, even if multiple components or episodes occur. Medical intervention is not required. Counts will be compared between study groups. |
Throughout the planned 36-month participant follow-up period.
|
|
Number of participants who die from any cause
Tidsramme: Throughout the planned 36-month participant follow-up period.
|
Number of participants who die from any cause during follow-up, compared between the ICM and standard-care groups. |
Throughout the planned 36-month participant follow-up period.
|
|
Number of participants who die from a cardiovascular cause
Tidsramme: Throughout the planned 36-month participant follow-up period.
|
Number of participants who die as a result of a cardiovascular complication, as defined in the protocol, compared between the ICM and standard-care groups. |
Throughout the planned 36-month participant follow-up period.
|
|
Number of participants with a documented cardiac arrhythmia
Tidsramme: Throughout the planned 36-month participant follow-up period.
|
Composite endpoint comprising documented cardiac arrhythmias as defined in the protocol. A participant is counted once upon documentation of any qualifying arrhythmia, regardless of the number or type of subsequent arrhythmias. Medical intervention is not required. Counts will be compared between study groups. |
Throughout the planned 36-month participant follow-up period.
|
|
Number of participants with documented bradycardia
Tidsramme: Throughout the planned 36-month participant follow-up period.
|
Number of participants with at least one documented episode of bradycardia meeting the protocol definition. Each participant is counted once. Counts will be reported by study group and according to whether bradycardia prompts medical intervention. |
Throughout the planned 36-month participant follow-up period.
|
|
Number of participants with documented sinus node dysfunction
Tidsramme: Throughout the planned 36-month participant follow-up period.
|
Number of participants with documented sinus node dysfunction. Each participant is counted once. Counts will be reported by study group and according to whether sinus node dysfunction prompts medical intervention. |
Throughout the planned 36-month participant follow-up period.
|
|
Number of participants with documented atrioventricular block
Tidsramme: Throughout the planned 36-month participant follow-up period.
|
Number of participants with documented atrioventricular block, classified using the protocol definitions. Each participant is counted once. Counts will be reported by study group and according to whether atrioventricular block prompts medical intervention. |
Throughout the planned 36-month participant follow-up period.
|
|
Number of participants with documented atrial fibrillation
Tidsramme: Throughout the planned 36-month participant follow-up period.
|
Number of participants with documented atrial fibrillation meeting the protocol definition. Each participant is counted once. Counts will be reported by study group and according to whether atrial fibrillation prompts medical intervention. |
Throughout the planned 36-month participant follow-up period.
|
|
Number of participants with documented supraventricular tachycardia other than atrial fibrillation
Tidsramme: Throughout the planned 36-month participant follow-up period.
|
Number of participants with documented supraventricular tachycardia other than atrial fibrillation, classified using the protocol definitions. Each participant is counted once. Counts will be reported by study group and according to whether the arrhythmia prompts medical intervention. |
Throughout the planned 36-month participant follow-up period.
|
|
Number of participants with documented non-sustained ventricular tachycardia
Tidsramme: Throughout the planned 36-month participant follow-up period.
|
Number of participants with documented non-sustained ventricular tachycardia (NSVT) meeting the protocol definition. Each participant is counted once. Counts will be reported by study group and according to whether NSVT prompts medical intervention. |
Throughout the planned 36-month participant follow-up period.
|
|
Number of participants with documented ventricular tachycardia
Tidsramme: Throughout the planned 36-month participant follow-up period.
|
Number of participants with documented ventricular tachycardia (VT) meeting the protocol definition. Each participant is counted once. Counts will be reported by study group and according to whether VT prompts medical intervention. |
Throughout the planned 36-month participant follow-up period.
|
|
Number of participants with documented ventricular fibrillation
Tidsramme: Throughout the planned 36-month participant follow-up period.
|
Number of participants with documented ventricular fibrillation (VF) meeting the protocol definition. Each participant is counted once. Counts will be reported by study group and according to whether VF prompts medical intervention. |
Throughout the planned 36-month participant follow-up period.
|
|
Number of participants receiving invasive interventions for cardiac arrhythmias
Tidsramme: Throughout the planned 36-month participant follow-up period.
|
Number of participants receiving at least one invasive clinical intervention for a documented cardiac arrhythmia. Each participant is counted once, regardless of the number of invasive interventions received. Counts will be compared between study groups. |
Throughout the planned 36-month participant follow-up period.
|
|
Number of participants with supraventricular arrhythmias necessitating clinical intervention
Tidsramme: Throughout the planned 36-month participant follow-up period.
|
Number of participants with at least one documented supraventricular arrhythmia that prompts clinical intervention. Each participant is counted once. Counts will be compared between the ICM and standard-care groups. |
Throughout the planned 36-month participant follow-up period.
|
|
Number of participants with bradycardia necessitating clinical intervention
Tidsramme: Throughout the planned 36-month participant follow-up period.
|
Number of participants with at least one documented episode of bradycardia that prompts clinical intervention. Each participant is counted once. Counts will be compared between the ICM and standard-care groups. |
Throughout the planned 36-month participant follow-up period.
|
|
Number of participants with ventricular arrhythmias necessitating clinical intervention
Tidsramme: Throughout the planned 36-month participant follow-up period.
|
Number of participants with at least one documented ventricular arrhythmia that prompts clinical intervention. Each participant is counted once. Counts will be compared between the ICM and standard-care groups. |
Throughout the planned 36-month participant follow-up period.
|
|
Number of participants receiving an implantable cardioverter-defibrillator
Tidsramme: Throughout the planned 36-month participant follow-up period.
|
Number of participants undergoing implantable cardioverter-defibrillator (ICD) implantation during follow-up. Each participant is counted once. Counts will be compared between study groups. |
Throughout the planned 36-month participant follow-up period.
|
|
Number of participants receiving a pacemaker
Tidsramme: Throughout the planned 36-month participant follow-up period.
|
Number of participants undergoing pacemaker implantation during follow-up. Each participant is counted once. Counts will be compared between study groups. |
Throughout the planned 36-month participant follow-up period.
|
|
Number of participants receiving appropriate implantable cardioverter-defibrillator therapy
Tidsramme: From ICD implantation through the end of the planned 36-month participant follow-up period.
|
Number of participants receiving at least one appropriate implantable cardioverter-defibrillator (ICD) therapy after ICD implantation. Each participant is counted once, regardless of the number of appropriate therapies received. |
From ICD implantation through the end of the planned 36-month participant follow-up period.
|
|
Number of participants with complications related to insertable cardiac monitor implantation
Tidsramme: From ICM implantation through the end of ICM follow-up, anticipated to last 36 months after implantation.
|
Number of participants in the ICM group experiencing at least one complication related to ICM implantation, including implantation-site infection, hematoma, or device migration. Each participant is counted once. Complication types will be reported as categories of the same participant-count measure. |
From ICM implantation through the end of ICM follow-up, anticipated to last 36 months after implantation.
|
|
Number of participants with suspected serious complications related to arrhythmia-directed clinical interventions
Tidsramme: Throughout the planned 36-month participant follow-up period.
|
Number of participants experiencing at least one suspected serious complication related to a clinical intervention performed for a detected cardiac arrhythmia. Each participant is counted once. Complication types will be reported as categories of the same participant-count measure. |
Throughout the planned 36-month participant follow-up period.
|
|
Number of participants meeting the composite health-risk endpoint
Tidsramme: Clinical events throughout the planned 36-month follow-up period; NYHA class assessed at baseline and 12, 24, and 36 months.
|
Composite endpoint comprising an increase of at least one NYHA class, heart failure admission, cardiovascular death, percutaneous coronary intervention, myocardial infarction, cerebrovascular accident, coronary artery bypass grafting, or valve surgery. A participant meets the endpoint if any component occurs and is counted once, regardless of the number of components experienced. Counts will be compared between study groups. |
Clinical events throughout the planned 36-month follow-up period; NYHA class assessed at baseline and 12, 24, and 36 months.
|
|
Percentage of participants with documented non-sustained ventricular tachycardia
Tidsramme: During the first 30 days and first 6 months after initiation of LUX monitoring.
|
Percentage of participants in the insertable cardiac monitor (ICM) group with at least one adjudicated non-sustained ventricular tachycardia (NSVT) episode during each assessment window. Each participant is counted once per window, regardless of the number of episodes. The percentage is calculated as the number of participants with NSVT divided by the number of participants in the analysis population, multiplied by 100. The numerator and denominator will also be reported. |
During the first 30 days and first 6 months after initiation of LUX monitoring.
|
|
Rate of non-sustained ventricular tachycardia episodes per monitoring day
Tidsramme: During the first 30 days and first 6 months after initiation of LUX monitoring.
|
Rate of all adjudicated non-sustained ventricular tachycardia (NSVT) episodes recorded by the insertable cardiac monitor (ICM). All qualifying episodes are counted, including recurrent episodes within the same participant. For each assessment window, the rate is calculated as the total number of NSVT episodes across participants in the ICM group divided by their total observed ICM monitoring time in days. NSVT is classified according to the protocol definition. |
During the first 30 days and first 6 months after initiation of LUX monitoring.
|
|
Percentage of participants with documented sustained ventricular tachycardia
Tidsramme: During the first 30 days and first 6 months after initiation of LUX monitoring.
|
Percentage of participants in the ICM group with at least one adjudicated sustained ventricular tachycardia (VT) episode during each assessment window. Each participant is counted once per window. The percentage is calculated as the number of participants with sustained VT divided by the number of participants in the analysis population, multiplied by 100. The numerator and denominator will also be reported. |
During the first 30 days and first 6 months after initiation of LUX monitoring.
|
|
Rate of documented sustained ventricular tachycardia episodes per monitoring day
Tidsramme: During the first 30 days and first 6 months after initiation of LUX monitoring
|
Rate of all adjudicated sustained VT episodes recorded by the ICM, including recurrent episodes within the same participant. For each assessment window, the rate is calculated as the total number of sustained VT episodes across participants in the ICM group divided by their total observed ICM monitoring time in days. Results are expressed as sustained VT episodes per monitoring day. |
During the first 30 days and first 6 months after initiation of LUX monitoring
|
|
Percentage of participants meeting the early composite PVC, NSVT, VT, or VF endpoin
Tidsramme: During the first 30 days and first 6 months of participant follow-up.
|
Percentage of participants meeting a composite endpoint comprising PVC, NSVT, sustained VT, or ventricular fibrillation (VF). A participant meets the endpoint if any component occurs and is counted once per assessment window. The percentage is calculated as the number of qualifying participants divided by the number in the analysis population, multiplied by 100, and compared between study groups. |
During the first 30 days and first 6 months of participant follow-up.
|
|
Rate of events meeting the early composite PVC, NSVT, VT, or VF endpoint
Tidsramme: During the first 30 days and first 6 months of participant follow-up.
|
Rate of events meeting the composite endpoint comprising PVC, NSVT, sustained VT, or VF. Qualifying events will be counted according to protocol description and divided by time of follow-up. Results will be compared between study groups. |
During the first 30 days and first 6 months of participant follow-up.
|
|
Mean premature ventricular contraction burden
Tidsramme: Throughout ICM monitoring, anticipated to last 36 months after implantation.
|
Mean premature ventricular contraction (PVC) burden recorded by the ICM in the ICM group. For each participant, daily device-recorded PVC burden, expressed as a percentage, will be averaged over the observation period. The participant-level averages will then be summarized as the group mean PVC burden |
Throughout ICM monitoring, anticipated to last 36 months after implantation.
|
|
Change from baseline in EQ-5D-5L score
Tidsramme: Baseline and 12, 24, and 36 months. Follow-up questionnaires are completed within 1 month of each scheduled assessment.
|
Health status assessed using the EQ-5D-5L specific score. Changes from baseline will be calculated at 12, 24, and 36 months and compared between the ICM and standard-care groups to assess differences in change over time. There is also an visual analogue sclae with scores that ranges from 0 to 100, with higher scores indicating better perception of being healthy. Changes will be summarized using these scores |
Baseline and 12, 24, and 36 months. Follow-up questionnaires are completed within 1 month of each scheduled assessment.
|
|
Change from baseline in self-assessed NYHA class
Tidsramme: Baseline and 12, 24, and 36 months. Follow-up questionnaires are completed within 1 month of each scheduled assessment.
|
Functional status assessed using self-assessed New York Heart Association (NYHA) class. Changes from baseline will be determined at 12, 24, and 36 months and compared between the ICM and standard-care groups. Changes will be reported as NYHA class. Higher NYHA classes indicate greater functional limitation. |
Baseline and 12, 24, and 36 months. Follow-up questionnaires are completed within 1 month of each scheduled assessment.
|
|
Change from the initial post-implant assessment in Florida Patient Acceptance Survey using the FPAS specific score
Tidsramme: Baseline and 12, 24, and 36 months. Follow-up questionnaires are completed within 1 month of each scheduled assessment.
|
Device acceptance assessed using the Florida Patient Acceptance Survey (FPAS) in the ICM group only. Changes from the initial post-implant assessment will be calculated at 12, 24, and 36 months to assess change over time. The score ranges from 0 to 100, with higher scores indicating better acceptance. |
Baseline and 12, 24, and 36 months. Follow-up questionnaires are completed within 1 month of each scheduled assessment.
|
|
NT-proBNP concentration
Tidsramme: Baseline: within 6 months before enrollment and after the most recent MI. Additional routine-care measurements throughout the planned 36-month follow-up.
|
NT-proBNP concentration measured in blood samples and expressed in ng/L. Baseline concentrations will be evaluated as a predictor of cardiac arrhythmias. Follow-up concentrations will be collected only when measured during routine clinical care. |
Baseline: within 6 months before enrollment and after the most recent MI. Additional routine-care measurements throughout the planned 36-month follow-up.
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Mean daily coffee intake assessed using the study questionnaire
Tidsramme: At baseline, 12-, 24-, and 36 months
|
Participant-reported coffee intake assessed using the additional study questionnaire and expressed as cups per day. The mean number of cups consumed per day will be calculated across participants with available questionnaire responses at each assessment. |
At baseline, 12-, 24-, and 36 months
|
|
Mean weekly alcohol intake assessed using the study questionnaire
Tidsramme: At baseline, 12-, 24-, and 36 months
|
Participant-reported alcohol intake assessed using the additional study questionnaire and expressed as standard drinks per week. Mean weekly intake will be calculated across participants with available questionnaire responses at each assessment. |
At baseline, 12-, 24-, and 36 months
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Reinoud E Knops, Prof, MD, PhD, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Scirica BM, Braunwald E, Belardinelli L, Hedgepeth CM, Spinar J, Wang W, Qin J, Karwatowska-Prokopczuk E, Verheugt FW, Morrow DA. Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2010 Aug 3;122(5):455-62. doi: 10.1161/CIRCULATIONAHA.110.937136. Epub 2010 Jul 19.
- Makikallio TH, Barthel P, Schneider R, Bauer A, Tapanainen JM, Tulppo MP, Schmidt G, Huikuri HV. Prediction of sudden cardiac death after acute myocardial infarction: role of Holter monitoring in the modern treatment era. Eur Heart J. 2005 Apr;26(8):762-9. doi: 10.1093/eurheartj/ehi188. Epub 2005 Mar 18.
- Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, Charron P, Corrado D, Dagres N, de Chillou C, Eckardt L, Friede T, Haugaa KH, Hocini M, Lambiase PD, Marijon E, Merino JL, Peichl P, Priori SG, Reichlin T, Schulz-Menger J, Sticherling C, Tzeis S, Verstrael A, Volterrani M; ESC Scientific Document Group. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022 Oct 21;43(40):3997-4126. doi: 10.1093/eurheartj/ehac262. No abstract available.
- Held C, White HD, Stewart RAH, Budaj A, Cannon CP, Hochman JS, Koenig W, Siegbahn A, Steg PG, Soffer J, Weaver WD, Ostlund O, Wallentin L; STABILITY Investigators. Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc. 2017 Oct 24;6(10):e005077. doi: 10.1161/JAHA.116.005077.
- Kutyifa V, Beck C, Brown MW, Cannom D, Daubert J, Estes M, Greenberg H, Goldenberg I, Hammes S, Huang D, Klein H, Knops R, Kosiborod M, Poole J, Schuger C, Singh JP, Solomon S, Wilber D, Zareba W, Moss AJ; MADIT S-ICD Executive Committee. Multicenter Automatic Defibrillator Implantation Trial-Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol. Am Heart J. 2017 Jul;189:158-166. doi: 10.1016/j.ahj.2017.04.014. Epub 2017 May 4.
- Kusumoto FM, Schoenfeld MH, Barrett C, Edgerton JR, Ellenbogen KA, Gold MR, Goldschlager NF, Hamilton RM, Joglar JA, Kim RJ, Lee R, Marine JE, McLeod CJ, Oken KR, Patton KK, Pellegrini CN, Selzman KA, Thompson A, Varosy PD. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2019 Aug 20;140(8):e382-e482. doi: 10.1161/CIR.0000000000000628. Epub 2018 Nov 6. No abstract available.
- Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, De Potter TJR, Dwight J, Guasti L, Hanke T, Jaarsma T, Lettino M, Lochen ML, Lumbers RT, Maesen B, Molgaard I, Rosano GMC, Sanders P, Schnabel RB, Suwalski P, Svennberg E, Tamargo J, Tica O, Traykov V, Tzeis S, Kotecha D; ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024 Sep 29;45(36):3314-3414. doi: 10.1093/eurheartj/ehae176. No abstract available.
- Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, Deswal A, Eckhardt LL, Goldberger ZD, Gopinathannair R, Gorenek B, Hess PL, Hlatky M, Hogan G, Ibeh C, Indik JH, Kido K, Kusumoto F, Link MS, Linta KT, Marcus GM, McCarthy PM, Patel N, Patton KK, Perez MV, Piccini JP, Russo AM, Sanders P, Streur MM, Thomas KL, Times S, Tisdale JE, Valente AM, Van Wagoner DR; Peer Review Committee Members. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024 Jan 2;149(1):e1-e156. doi: 10.1161/CIR.0000000000001193. Epub 2023 Nov 30.
- Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, Barrabes JA, Boriani G, Braunschweig F, Brignole M, Burri H, Coats AJS, Deharo JC, Delgado V, Diller GP, Israel CW, Keren A, Knops RE, Kotecha D, Leclercq C, Merkely B, Starck C, Thylen I, Tolosana JM; ESC Scientific Document Group. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021 Sep 14;42(35):3427-3520. doi: 10.1093/eurheartj/ehab364. No abstract available.
- Richards M, Garner JB, Rogers JD, Mahajan D, Ravikumar V, Herrmann KL, Schwartz T, Okeson B, Kupfer ME, Stolen CM, Bavikati VV, Dukes JW, Manyam H, Pokorney SD; LUX-Dx PERFORM Investigators. Safety, performance, and remote programming utilization of an insertable cardiac monitor: The LUX-Dx PERFORM study. Heart Rhythm O2. 2026 Feb 2;7(4):695-705. doi: 10.1016/j.hroo.2026.01.026. eCollection 2026 Apr.
- Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, Hammill SC, Hlatky MA, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018 Sep 25;138(13):e272-e391. doi: 10.1161/CIR.0000000000000549. No abstract available.
- Liu M, Lopez de Juan Abad B, Cheng K. Cardiac fibrosis: Myofibroblast-mediated pathological regulation and drug delivery strategies. Adv Drug Deliv Rev. 2021 Jun;173:504-519. doi: 10.1016/j.addr.2021.03.021. Epub 2021 Apr 5.
- Liu CY, Heckbert SR, Lai S, Ambale-Venkatesh B, Ostovaneh MR, McClelland RL, Lima JAC, Bluemke DA. Association of Elevated NT-proBNP With Myocardial Fibrosis in the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol. 2017 Dec 26;70(25):3102-3109. doi: 10.1016/j.jacc.2017.10.044.
- Orringer CE. C-reactive protein in people with high lipoprotein a: a partner in crime or an innocent bystander? Eur Heart J. 2023 Apr 21;44(16):1461-1463. doi: 10.1093/eurheartj/ehad080. No abstract available.
- Small AM, Pournamdari A, Melloni GEM, Scirica BM, Bhatt DL, Raz I, Braunwald E, Giugliano RP, Sabatine MS, Peloso GM, Marston NA, Natarajan P. Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention Populations. JAMA Cardiol. 2024 Apr 1;9(4):385-391. doi: 10.1001/jamacardio.2023.5605.
- Li S, Wang Y, Yang W, Zhou D, Zhuang B, Xu J, He J, Yin G, Fan X, Wu W, Sharma P, Sirajuddin A, Arai AE, Zhao S, Lu M. Cardiac MRI Risk Stratification for Dilated Cardiomyopathy with Left Ventricular Ejection Fraction of 35% or Higher. Radiology. 2023 Mar;306(3):e213059. doi: 10.1148/radiol.213059. Epub 2022 Nov 1.
- Disertori M, Rigoni M, Pace N, Casolo G, Mase M, Gonzini L, Lucci D, Nollo G, Ravelli F. Myocardial Fibrosis Assessment by LGE Is a Powerful Predictor of Ventricular Tachyarrhythmias in Ischemic and Nonischemic LV Dysfunction: A Meta-Analysis. JACC Cardiovasc Imaging. 2016 Sep;9(9):1046-1055. doi: 10.1016/j.jcmg.2016.01.033. Epub 2016 Jul 20.
- Bauer A, Sappler N, von Stulpnagel L, Klemm M, Schreinlechner M, Wenner F, Schier J, Al Tawil A, Dolejsi T, Krasniqi A, Eiffener E, Bongarth C, Stuhlinger M, Huemer M, Gori T, Wakili R, Sahin R, Schwinger R, Lutz M, Luik A, Gessler N, Clemmensen P, Linke A, Maier LS, Hinterseer M, Busch MC, Blaschke F, Sack S, Lennerz C, Licka M, Tilz RR, Ukena C, Ehrlich JR, Zabel M, Schmidt G, Mansmann U, Kaab S, Rizas KD, Massberg S; SMART-MI-DZHK9 investigators. Telemedical cardiac risk assessment by implantable cardiac monitors in patients after myocardial infarction with autonomic dysfunction (SMART-MI-DZHK9): a prospective investigator-initiated, randomised, multicentre, open-label, diagnostic trial. Lancet Digit Health. 2022 Feb;4(2):e105-e116. doi: 10.1016/S2589-7500(21)00253-3.
- Makimoto H, Zielke S, Clasen L, Lin T, Gerguri S, Muller P, Schmidt J, Bejinariu A, Kurt M, Brinkmeyer C, Stern M, Kelm M, Furnkranz A. Clinical significance of precedent asymptomatic non-sustained ventricular tachycardias on subsequent ICD interventions and heart failure hospitalization in primary prevention ICD patients. Eur J Med Res. 2020 Mar 17;25(1):5. doi: 10.1186/s40001-020-0401-x.
- Hashimoto K, Amino M, Yoshioka K, Kasamaki Y, Kinoshita T, Ikeda T. Combined evaluation of ambulatory-based late potentials and nonsustained ventricular tachycardia to predict arrhythmic events in patients with previous myocardial infarction: A Japanese noninvasive electrocardiographic risk stratification of sudden cardiac death (JANIES) substudy. Ann Noninvasive Electrocardiol. 2021 Jan;26(1):e12803. doi: 10.1111/anec.12803. Epub 2020 Sep 24.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- NL-010971
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .